Cabaletta Bio, Inc. Updates Corporate Presentation on October 29, 2025

On October 29, 2025, Cabaletta Bio, Inc. updated its corporate presentation and posted it to the 'Investors & Media' section of its website. The presentation highlights the company's progress in developing rese-cel, an autologous CD19-CAR T cell therapy for autoimmune diseases. Key updates include the initiation of a registrational cohort for myositis in Q4 2025, with plans for a BLA submission in 2027. The presentation also outlines the company's strategy to expand the use of rese-cel across multiple autoimmune indications, including systemic lupus erythematosus (SLE), systemic sclerosis (SSc), and myasthenia gravis (MG). The company has achieved FDA alignment on the registrational design for myositis and anticipates similar alignment for other indications in the near future. The presentation emphasizes the transformative potential of rese-cel in providing durable, drug-free responses for patients with refractory autoimmune diseases.